Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Perspective Therapeutics (CATX) Other Non-Current Assets (2016 - 2025)

Perspective Therapeutics (CATX) has disclosed Other Non-Current Assets for 15 consecutive years, with $486000.0 as the latest value for Q4 2025.

  • Quarterly Other Non-Current Assets rose 20.0% to $486000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $486000.0 through Dec 2025, up 20.0% year-over-year, with the annual reading at $486000.0 for FY2025, 20.0% up from the prior year.
  • Other Non-Current Assets hit $486000.0 in Q4 2025 for Perspective Therapeutics, up from $438000.0 in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $4.1 million in Q4 2022 to a low of $110000.0 in Q4 2021.
  • Historically, Other Non-Current Assets has averaged $454058.8 across 5 years, with a median of $182000.0 in 2021.
  • Biggest five-year swings in Other Non-Current Assets: skyrocketed 3670.91% in 2022 and later crashed 95.61% in 2023.
  • Year by year, Other Non-Current Assets stood at $110000.0 in 2021, then surged by 3670.91% to $4.1 million in 2022, then plummeted by 95.61% to $182000.0 in 2023, then skyrocketed by 122.53% to $405000.0 in 2024, then rose by 20.0% to $486000.0 in 2025.
  • Business Quant data shows Other Non-Current Assets for CATX at $486000.0 in Q4 2025, $438000.0 in Q3 2025, and $405000.0 in Q4 2024.